Sbir topic 307 phase i novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201100120C
Awardee
Awarding agency
Obligated
$224,264

Award facts

Contract value 100% obligated
$224,264.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 16 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Inglewood, CA 90301, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $224,264

About this award

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Imaginab, Inc. The contract, valued at $224,264, is for the development of novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract has a firm fixed-price pricing type and a completion date of September 29, 2012.

Quick answers

Who was awarded contract HHSN261201100120C?

HHSN261201100120C was awarded to Imaginab, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2011.

How much is contract HHSN261201100120C worth?

The government has obligated $224,264 on HHSN261201100120C.

Was contract HHSN261201100120C competed?

The extent of competition for HHSN261201100120C was full and open competition after exclusion of sources. The government received 16 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award